This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Volunteers needed for latest UK COVID-19 vaccine study launched in the West Midlands

valneva phase 3

 Volunteers from the West Midlands are being asked to sign up to the latest COVID-19 vaccine study to be rolled out across the UK.

The National Institute for Health Research (NIHR)-supported Valneva Phase 2/3 study, is open to healthy adults who have not had a previous COVID-19 vaccine.

It will be run at University Hospitals Coventry & Warwickshire NHS Trust, University Hospitals Birmingham NHS Foundation Trust and Midlands Partnership NHS Foundation Trust.

Four thousand participants will be recruited across the UK, and everyone involved in the study will receive two active vaccine doses, administered in a four week interval. Those enrolled in the study over the age of 30 will be randomised to receive two doses of either the Valneva vaccine, or the approved Oxford/AstraZeneca vaccine.

Participants aged 18 - 29 can be enrolled into the study to receive the Valneva vaccine and will not be offered the approved Oxford/AstraZeneca vaccine.

Developed by the specialty vaccine company Valneva, the vaccine is being manufactured at the company’s site in Livingston, West Lothian, and is the only inactivated, adjuvanted (an ingredient to create a stronger immune response) COVID-19 vaccine in clinical development in Europe.

Volunteers for the study will be vaccinated at the beginning of May, and a proportion of potential participants will be identified through the NHS COVID-19 Vaccine Research Registry, which currently has over 480,000 sign ups. Subject to successful Phase 2/3 data, Valneva aims to make regulatory submissions for initial approval in the autumn of 2021.

If Valneva’s vaccine is shown to be safe and effective, up to 250 million vaccine doses could be supplied to the UK and other countries around the world. As part of the UK government’s vaccine procurement approach, up to 100 million doses of this vaccine have been secured.

To register interest in vaccine studies and sign up to be contacted by researchers, people can visit the NHS COVID-19 Vaccine Research Registry www.nhs.uk/researchcontact.

Professor Adam Finn, Chief Investigator for the Valneva study said:
“Following very encouraging safety and immune response results from our phase 1 study, along with my investigator colleagues, I am really looking forward to starting on this important next stage of the clinical development of this important new vaccine.

“We definitely need more vaccines to help us out of this pandemic and this one is very promising.”

Professor Matthew Brookes, Acting Clinical Director of the NIHR Clinical Research Network West Midlands added:
“Clinical studies into COVID-19 vaccines remain critical to help find several safe and effective candidates to help protect us all. Volunteers in the West Midlands are still needed to help carry out these studies and we are very grateful to the more than 30,000 who have already signed up.”

Professor Andrew Ustianowski, National Clinical Lead for the UK NIHR COVID Vaccine Research Programme, said:
“Off the back of positive early study data, it is great to see the final stage of the Valneva study begin across the UK, coordinated by the NIHR Clinical Research Network. Evaluating an additional vaccine candidate to help protect the population against COVID-19 is vital in our efforts to ensure that we have effective vaccines that work for everybody.

"Each and every one of the participants involved in the study are key to helping us gain a detailed understanding of how the vaccine will perform in a large population.

"People are still needed from all backgrounds to take part in this and future vaccine studies. Signing up to be contacted, if you are interested in taking part in vaccine studies, is simple via the NHS Vaccine Research Registry."

Thomas Lingelbach, Chief Executive Officer of Valneva, said:
“As COVID-19 continues to impact people’s daily lives, Valneva remains fully focused on developing another safe and efficacious vaccine solution. The world needs multiple vaccines and we believe that ours has an important role to play - including boosters or potential modifications to address variants.

“The initiation of this trial marks a significant milestone in the development of the only inactivated vaccine candidate against COVID-19 in clinical trials in Europe. We are grateful to the NIHR for its continued support and to everyone who volunteers to make clinical trials possible.”

ENDS

For more information locally, contact Communications Lead Claire Hall on 07775 800227 claireanne.hall@nihr.ac.uk

About the Valneva Study (Non-inferiority study comparing immunogenicity against COVID-19 of VLA2001 with [ACTIVE COMPARATOR]):

Positive safety and immunogenicity study results from the Phase 1/2 stage showed the study vaccine dose was “well tolerated with no safety concerns identified”.

There are expected to be 4,000 volunteers across 22 NIHR sites, and two Devolved Administration sites different sites in the trial, including:

University Hospitals Coventry & Warwickshire
University Hospitals Birmingham NHS Foundation Trust
Midlands Partnership NHS Foundation Trust
NIHR Cambridge Biomedical Research Centre
Royal Surrey NHS Foundation Trust
Lakeside Healthcare Research, Corby
Nottingham University Hospitals NHS Trust
Northern Care Alliance NHS Group, Salford
Liverpool University Hospitals NHS Foundation Trust
Blackpool Teaching Hospitals NHS Foundation Trust
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Northumbria Healthcare NHS Foundation Trust
Royal Free London NHS Foundation Trust
University College London Hospitals NHS Foundation Trust
Chelsea and Westminster Hospital
St George's University Hospitals NHS Foundation Trust
University Hospitals Plymouth NHS Trust
Southampton University Hospitals NHS Trust
University Hospitals Bristol and Weston NHS Foundation Trust
North Bristol NHS Trust
Cheadle Hospital, Midlands Partnership NHS Foundation Trust
Barnsley Hospital NHS Foundation Trust
Warrington and Halton Teaching Hospitals NHS Foundation Trust
Queen Elizabeth Hospital-Glasgow- NHS Greater Glasgow
Western General Hospital, Edinburgh- NHS Lothian

About the National Institute for Health Research

The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
Funds, supports and delivers high quality research that benefits the NHS, public health and social care
Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

Volunteering for COVID-19 vaccine clinical trials:

People wishing to volunteer to support clinical trials can sign up for information on Covid-19 vaccine trials with the NHS Covid-19 Vaccine Research Registry, developed in partnership with NHS Digital. It is helping large numbers of people to be recruited into trials.
The service was commissioned as part of the UK Government’s Vaccine Taskforce in conjunction with the National Institute for Health Research (NIHR) and the Northern Ireland, Scottish and Welsh Governments.

Anyone living in the UK can sign up online to take part in the trials through the NHS, giving permission for researchers to contact you if they think you’re a good fit. Once you sign up, you can withdraw at any time and request that your details be removed from the COVID-19 Vaccine Research Registry. The process takes about 5 minutes to complete.

More information can be found: NHS.UK/coronavirus

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options.

We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to address these diseases. We have leveraged our expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

About VLA2001

VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants.


VLA2001 may also be suited for boosting,as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines.
VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO ® . VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B ® vaccine. The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes inactivation with BPL to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees Celsius).